Cloudbreak Pharma Inc. (HKG:2592)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Research and Developments of Therapeutic Biologics	253.00K	10.21M	880.00K	471.00K
Research and Developments of Therapeutic Biologics Growth	-97.52%	1060.68%	86.84%	-
Total	253.00K	10.21M	880.00K	471.00K
Total Growth	-97.52%	1060.68%	86.84%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024
Period Ending	Dec 31, 2024
United States	10.00M
Total	10.00M

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 17, 2026

Data Sources Report a data error